Anthropic's FOMO trade could be a costly mistake
Anthropic's FOMO trade could be a costly mistake
About this video
Key points:
Anthropic's blockbuster IPO has put AI valuations under fresh scrutiny.
NextDC looks undervalued, but power constraints and debt remain key risks.
Pro Medicus lands a $130 million US deal, with further AI upside ahead.
Anthropic's record-breaking IPO has reignited debate around AI valuations and the sustainability of the broader tech trade. Ryan McCaugherty from Sandstone Insights says investors should resist the fear of missing out, pointing to historical IPO performance and opportunities emerging elsewhere in the market.
NextDC has lifted its revenue and EBITDA guidance after an earlier downgrade, but questions remain around its M3 power connection and the cost of developing new data centre capacity. McCaugherty sees value in the company's existing assets, although debt levels and the path to monetising M3 could limit near-term upside.
Pro Medicus has secured a near $130 million contract with a New York hospital group, displacing a key competitor in a ten-year agreement. McCaugherty sees further growth potential from higher scan volumes and the rollout of AI-enabled software, while a possible shift in the RBA's rate outlook could provide relief for retail stocks heading into the Christmas trading period.